• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

DuPont Pharmaceuticals merges with BMS

Article

Bristol-Myers Squibb has completed its $7.8 billion purchase of DuPont Pharma. The acquisition, which was announced on June 7, closed Oct. 1. DuPont Pharma is expected to promote BMS growth by providing a greater focus on its medicine business. Among the

Bristol-Myers Squibb has completed its $7.8 billion purchase of DuPont Pharma. The acquisition, which was announced on June 7, closed Oct. 1. DuPont Pharma is expected to promote BMS growth by providing a greater focus on its medicine business. Among the myriad drugs in the DuPont portfolio is the technetium-based cardiac radiopharmaceutical Cardiolite. Under the terms of the agreement, Bristol-Myers Squibb paid the $7.8 billion in cash. The transaction is expected to be accretive to earnings beginning in 2003.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.